Profile data is unavailable for this security.
About the company
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is also developing a range of novel CNS product candidates, including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial products, including Qelbree (viloxazine), GOCOVRI (amantadine), Oxtellar XR (oxcarbazepine), Trokendi XR (topiramate), APOKYN (apomorphine hydrochloride injection) and others. Qelbree (viloxazine) is a novel non-stimulant product indicated for the treatment of ADHD.
- Revenue in USD (TTM)607.52m
- Net income in USD1.32m
- Incorporated2005
- Employees652.00
- LocationSupernus Pharmaceuticals Inc9715 Key West AvenueROCKVILLE 20850United StatesUSA
- Phone+1 (301) 838-2500
- Fax+1 (302) 636-5454
- Websitehttps://www.supernus.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Edgewise Therapeutics Inc | 0.00 | -100.16m | 1.50bn | 88.00 | -- | 3.56 | -- | -- | -1.57 | -1.57 | 0.00 | 4.53 | 0.00 | -- | -- | 0.00 | -28.33 | -- | -29.73 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.08 | -- | -- | -- |
| Neumora Therapeutics Inc | 0.00 | -235.93m | 1.52bn | 124.00 | -- | 3.25 | -- | -- | -2.33 | -2.33 | 0.00 | 2.95 | 0.00 | -- | -- | 0.00 | -51.15 | -- | -54.01 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.23 | -- | -- | -- |
| Taro Pharmaceutical Industries Ltd | 610.83m | 45.70m | 1.59bn | 1.55k | 34.71 | 0.8916 | 19.98 | 2.60 | 1.22 | 1.22 | 16.25 | 47.33 | 0.2854 | 1.45 | 2.76 | 393,068.20 | 2.14 | 1.85 | 2.59 | 2.21 | 48.02 | 56.82 | 7.48 | 6.99 | 3.03 | -- | 0.00 | 0.00 | 2.07 | -2.85 | -56.33 | -34.53 | -7.64 | -- |
| Avadel Pharmaceuticals PLC (ADR) | 27.96m | -160.28m | 1.60bn | 154.00 | -- | 18.09 | -- | 57.20 | -2.04 | -2.04 | 0.3491 | 0.9768 | 0.188 | -- | 4.52 | 181,577.90 | -107.75 | -40.21 | -156.49 | -47.99 | 96.97 | -- | -573.17 | -374.75 | 3.36 | -13.94 | 0.00 | -- | -- | -22.99 | -16.59 | -- | -- | -- |
| Inhibrx Inc | 1.80m | -241.36m | 1.63bn | 166.00 | -- | 37.44 | -- | 905.20 | -5.03 | -5.03 | 0.0382 | 0.9184 | 0.006 | -- | 3.53 | 10,843.37 | -80.07 | -77.06 | -93.12 | -93.91 | -- | -- | -13,318.17 | -1,590.91 | -- | -11.00 | 0.8263 | -- | -17.88 | -26.85 | -66.20 | -- | 26.30 | -- |
| Supernus Pharmaceuticals Inc | 607.52m | 1.32m | 1.66bn | 652.00 | 1,193.69 | 1.80 | 19.21 | 2.73 | -0.0152 | -0.0152 | 10.71 | 16.84 | 0.4077 | 0.9918 | 3.92 | 931,780.70 | 0.0883 | 4.95 | 0.1315 | 6.41 | 86.21 | 88.61 | 0.2166 | 12.84 | 1.43 | -- | 0.00 | -- | -8.95 | 8.24 | -97.83 | -58.81 | -8.17 | -- |
| Harmony Biosciences Holdings Inc | 582.02m | 128.85m | 1.66bn | 246.00 | 13.71 | 3.55 | 10.83 | 2.85 | 2.13 | 2.13 | 9.64 | 8.23 | 0.7837 | 25.10 | 9.03 | 2,365,943.00 | 17.35 | 7.46 | 20.74 | 9.08 | 79.17 | 80.58 | 22.14 | 10.46 | 2.72 | 21.27 | 0.293 | 0.00 | 32.93 | -- | -28.99 | -- | -25.31 | -- |
| Myriad Genetics, Inc. | 753.20m | -263.30m | 1.69bn | 2.70k | -- | 2.14 | -- | 2.24 | -3.20 | -3.20 | 9.09 | 8.71 | 0.6423 | 11.22 | 6.98 | 278,963.00 | -22.45 | -- | -25.66 | -- | 68.64 | -- | -34.96 | -- | 1.87 | -342.25 | 0.0469 | -- | 11.03 | -- | -135.09 | -- | -- | -- |
| Structure Therapeutics Inc (ADR) | 0.00 | -89.62m | 1.70bn | 93.00 | -- | 3.73 | -- | -- | -2.51 | -2.51 | 0.00 | 9.76 | 0.00 | -- | -- | 0.00 | -30.91 | -- | -33.06 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -69.62 | -- | -- | -- |
| Ginkgo Bioworks Holdings Inc | 251.46m | -892.87m | 1.72bn | 1.22k | -- | 1.54 | -- | 6.84 | -0.459 | -0.459 | 0.1293 | 0.5482 | 0.1196 | 24.49 | 5.01 | 206,449.10 | -42.47 | -- | -46.17 | -- | 78.52 | -- | -355.08 | -- | 6.11 | -1,703.31 | 0.00 | -- | -47.36 | -- | 57.58 | -- | -- | -- |
| Syndax Pharmaceuticals Inc | 0.00 | -209.36m | 1.77bn | 112.00 | -- | 3.18 | -- | -- | -2.96 | -2.96 | 0.00 | 6.53 | 0.00 | -- | -- | 0.00 | -37.72 | -27.90 | -40.93 | -30.15 | -- | -- | -- | -324.34 | -- | -- | 0.00004 | -- | -- | -- | -40.19 | -- | -- | -- |
| Twist Bioscience Corp | 262.36m | -205.80m | 1.78bn | 919.00 | -- | 3.01 | -- | 6.78 | -3.60 | -3.60 | 4.59 | 10.21 | 0.3194 | 4.47 | 7.04 | 285,488.60 | -25.06 | -30.50 | -27.56 | -33.84 | 35.79 | 36.02 | -78.44 | -113.33 | 5.51 | -- | 0.00 | -- | 20.41 | 57.33 | 6.08 | -- | 49.76 | -- |
| Agios Pharmaceuticals Inc | 26.82m | -352.09m | 1.78bn | 383.00 | -- | 2.18 | -- | 66.35 | -6.33 | -6.33 | 0.482 | 14.50 | 0.0247 | 0.209 | 10.69 | 70,033.95 | -32.36 | -29.54 | -34.43 | -31.88 | 89.26 | -- | -1,312.64 | -3,826.10 | 11.99 | -- | 0.00 | -- | 88.36 | -22.25 | -51.89 | -- | -32.23 | -- |
| Catalyst Pharmaceuticals Inc | 398.20m | 71.41m | 1.78bn | 167.00 | 24.82 | 4.18 | 17.11 | 4.48 | 0.6092 | 0.6092 | 3.56 | 3.62 | 0.9417 | 4.63 | 12.45 | 2,384,455.00 | 16.89 | 25.42 | 20.06 | 29.81 | 86.95 | 85.63 | 17.93 | 30.87 | 2.68 | -- | 0.00 | 0.00 | 85.90 | 280.39 | -14.05 | -- | 20.21 | -- |
Data as of Apr 25 2024. Currency figures normalised to Supernus Pharmaceuticals Inc's reporting currency: US Dollar USD
61.25%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2023 | 8.69m | 15.88% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 6.07m | 11.09% |
| Armistice Capital LLCas of 31 Dec 2023 | 4.65m | 8.50% |
| Macquarie Investment Management Business Trustas of 31 Dec 2023 | 2.74m | 5.00% |
| Dimensional Fund Advisors LPas of 31 Dec 2023 | 2.46m | 4.49% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 2.06m | 3.77% |
| Polar Capital LLPas of 31 Dec 2023 | 1.94m | 3.54% |
| Stephens Investment Management Group LLCas of 31 Dec 2023 | 1.90m | 3.48% |
| Loomis, Sayles & Co. LPas of 31 Dec 2023 | 1.64m | 2.99% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 1.38m | 2.52% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
